MAZE THERAPEUTICS, INC. (MAZE) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 22.96M USD | Liabilities, Current |
| Cash and equivalents | 202.64M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 208.44M USD | Marketable Securities, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $22.96M | $202.64M | $208.44M | (m) | (m) | (m) |
| 2026-03-31 | $372.38M | $21.24M | $198.77M | $153.62M | $20.00M | (m) | 17.54× |
| 2025-12-31 | (m) | $22.56M | $189.25M | $152.67M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $22.11M | $316.77M | $67.16M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $19.90M | $264.54M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $18.62M | $294.37M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $20.67M | $196.81M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | (m) | $149.61M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | $175.06M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | $30.02M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |